Personalis (PSNL) Fundamentals 2026 — Revenue Analysis | SniperIQ
Personalis (PSNL) is a US-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Personalis's market cap?
Personalis (PSNL) has a market capitalization of approximately
What is Personalis's P/E ratio?
Personalis's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 5.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Personalis?
Personalis runs a net profit margin of -148.1%, a gross margin of 13.7%, and an operating margin of -158.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Personalis pay a dividend?
Personalis does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Personalis financially healthy?
Personalis carries a debt-to-equity ratio of 0.15x and a current ratio of 6.61x, with a market beta of 2.24. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Personalis a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Personalis (PSNL) the key facts are: market cap
Track Personalis's full fundamentals live
Get Personalis's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.